Search

for
Search:

Research

5 / 1000+ results

research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment

3 citations , October 2025 in “Cancer”

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

research Dihydrotestosterone induces p27 degradation via direct binding with SKP2 in ovarian and breast cancer

18 citations , April 2011 in “International Journal of Molecular Medicine”

This study found that dihydrotestosterone (DHT) regulates the degradation of p27 in MCF-7 breast cancer and OVCAR-3 ovarian cancer cells, involving SKP2 as a key factor.

research Lipid-based liquid crystals as drug delivery vehicles for antimicrobial peptides

5 citations , January 2017 in “Chalmers Publication Library (Chalmers University of Technology)”

In this study, cubosome and hexosome carriers with antimicrobial peptides showed varied efficacy, with cubosomes protecting peptides from degradation and enhancing bactericidal effects in some cases, while hexosomes lacked antimicrobial activity.

research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions

9 citations , October 2025 in “MedComm”

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

research Molecular elements of the regulatory control of keratin filament modulator AHF/trichohyalin in the hair follicle

7 citations , July 2008 in “Experimental Dermatology”

This study identified molecular elements controlling the expression and stabilization of THH protein in hair follicle cells, revealing key mechanisms that support hair shaft development in mice.

View more "proteolytic degradation" in research →

Community Join

2 / 1000+ results

community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁

276 upvotes 6 months ago

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

View more "proteolytic degradation" in community →

Learn

3 / 801 results

learn GT20029

research compound made to degrade androgen receptors in scalp

learn Hydrolyzed proteins

learn Hydrolyzed protein

View more "proteolytic degradation" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →